FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPRO	OVAL				
	OMB Number:	3235-0287				
Estimated average burden						
l	hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					01	Occin	011 00(11)	JI 1110	vcoanc	111 00	inpuriy 7 tot	01 10-10						
1. Name and Address of Reporting Person* Biller Scott					2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC AGIO								neck all appli Directo	cable) or (give title	g Person(s) to Issi 10% Ow Other (s below)		vner	
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET					Date o		Trans	action (M	1onth/	/Day/Year)		,	Chief Scientific					
(Street) CAMBRIDGE MA 02139				_	If Ame	ndment, I	Date o	of Origina	l Filed	d (Month/Da		Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(5		(Zip)															
			ole I - No			_			-	, Dis	_			ly Owned				
Da			Date	. Transaction late Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)					Benefici Owned I	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	orted saction(s) tr. 3 and 4)			(Instr. 4)	
Common stock 12			12/06	6/2017	/2017		M		14,875	5 A	\$0.46	75 21	21,139		D			
Common stock 12			12/06	6/2017	7			M		102	A	\$0.46	75 21	1,241		D		
Common stock 12/06			6/2017	2017		M		31,818	3 A	\$2.33	75 53	3,059		D				
		-	Table II -	Deriva (e.a., ı	ative puts.	Secu	urities .	Acqı ants	uired, I . optio	Disp	osed of, convertil	or Bend	eficially irities)	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion Date Execution I fany (Month/Day/Year) Derivative Security 3. Transaction Execution I Execution I fany (Month/Day/Year)		ed 4. Date, Transactio		ection	5. Number of		6. Date Exercisable ar Expiration Date (Month/Day/Year)		sable and	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares					
Stock option (right to buy)	\$0.4675	12/06/2017			M		14,875		(1)		12/06/2020	Common stock	14,875	\$0.00	0		D	
Stock option (right to buy)	\$0.4675	12/06/2017			M		102		(2)		12/06/2020	Common stock	102	\$0.00	4,867	,	D	
Stock option (right to	\$2.3375	12/06/2017			M		31,818		(3)		04/05/2022	Common stock	31,818	\$0.00	31,818	8	D	

Explanation of Responses:

- 1. This option was granted on December 7, 2010. The shares underlying this option vest as to 25% of the shares on September 20, 2011, with the remaining 75% vesting in 36 equal monthly installments thereafter
- 2. This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015.
- 3. This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares, and the remaining 15,909 shares vested on April 4, 2015.

Remarks:

/s/ William Cook, as Attorneyin-fact for Scott Biller

12/08/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.